Ulcerative Colitis associated with Sclerosing Cholangitis and Autoimmune Hepatitis

1. Hyams JS. Inflammatory Bowel Disease. in: Kliegman RM, Behrman RE, Jenson HB, Stanton BF. ed. Nelson Text Took of Pediatrics. 18 th ed. New Delhi: Elsevier Inc.; 2007:1575-85.Search in Google Scholar

2. Xanthakos SA, Balistreri WF. Liver Disease Associated with Systemic Disorders. in: Kliegman RM, Behrman RE, Jenson HB, Stanton BF. ed. Nelson Text Took of Pediatrics. 18 th ed. New Delhi: Elsevier Inc.; 2007:1692-5.Search in Google Scholar

3. Woodward J, Neuberger J. Autoimmune overlap syndromes. Hepatology. 2001 Apr;33(4):994-1002.10.1053/jhep.2001.23316Search in Google Scholar

4. Hubscher G. Pathology of vanishing bile duct syndromes. in: Neuberger J ed. Primary Biliary Cirrhosis. Eastbourne: West End Studios; 2000. p. 41-52.Search in Google Scholar

5. Mackay I-R. Historical reflections on autoimmune hepatitis. World J. Gastroenterol. 2008 Jun 7;14(21):3292-300.10.3748/wjg.14.3292Search in Google Scholar

6. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study. Gastroenterology. 2007 Aug;133(2):423-32.10.1053/j.gastro.2007.05.029Search in Google Scholar

7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987 Dec 24;317(26):1625-9.10.1056/NEJM198712243172603Search in Google Scholar

8. Primary Sclerosing Cholangitis. suite101.com [Internet]. [cited 2012 Apr 4]; Available from: http://elaine-moore.suite101.com/primary-sclerosingcholangitis-a13444Search in Google Scholar

9. Autoimmune Hepatitis. suite101.com [Internet]. [cited 2012 Apr 7]; Available from: http://wendyamprosser.suite101.com/autoimmunehepatitis-a202937Search in Google Scholar

10. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 1999 Nov;31(5):929-38.10.1016/S0168-8278(99)80297-9Search in Google Scholar

11. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993 Oct;18(4):998-1005.10.1002/hep.1840180435Search in Google Scholar

12. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology. 1998 Aug;28(2):360-5.10.1002/hep.510280210Search in Google Scholar

13. Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology. 1993 Jul;18(1):10-5.10.1002/hep.1840180103Search in Google Scholar

14. Colombato LA, Alvarez F, Côté J, Huet PM. Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology. 1994 Dec;107(6):1839-43.10.1016/0016-5085(94)90829-XSearch in Google Scholar

15. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996 Nov;24(5):1068-73.10.1002/hep.5102405158903377Search in Google Scholar

16. Toh BH. Smooth muscle autoantibodies and autoantigens. Clin Exp Immunol. 1979 Dec;38(3):621-8.Search in Google Scholar

17. Strassburg CP, Manns MP. Autoantibodies and Autoantigens in Autoimmune Hepatitis. Seminars in Liver Disease. 2002;22(4):339-52.10.1055/s-2002-35704Search in Google Scholar

18. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am. J. Gastroenterol. 2004 Nov;99(11):2235-41.10.1111/j.1572-0241.2004.40369.xSearch in Google Scholar

19. Vermeire S, Assche GV, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nature Reviews Gastroenterology and Hepatology. 2005 Dec 1;2(12):580-6.10.1038/ncpgasthep0359Search in Google Scholar

20. A H, I S, I S, Oana B, Andrea M. Successful Treatment with Infliximab in a Case of Crohn’s Disease with Peripheral Arthropathyes. Acta Medica Marisiensis. 2011 Apr 1;57(3):256-9.Search in Google Scholar

21. Hoduț A, Simedrea I, Belei O, Militaru A, Raluca B, Brad G. Acute Infusion Reaction to Infliximab in a Case of Crohn’s Disease with Recto-Scrotal Fistula. Acta Medica Marisiensis. 2011 Dec 7;57(5):544-7.Search in Google Scholar

22. Fagerhol MK, Dale I, Anderson T. Release and Quantitation of a Leucocyte Derived Protein (L1). Scandinavian Journal of Haematology. 1980 Dec 1;24(5):393-8.10.1111/j.1600-0609.1980.tb02754.xSearch in Google Scholar

23. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK. Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet. 1990 Sep 29;336(8718):763-5.10.1016/0140-6736(90)93237-JSearch in Google Scholar

24. El Saadany Sherif, Wael Farrag Mohamed, Abdullah A. Mohamed, Sahar A.F. Hammoudah. Fecal Calprotectin as a Marker in Differentiating Irritable Bowel Syndrome from Organic Intestinal Disease. elsadany66 [Internet]. [cited 2012 Apr 3]; Available from: http://elsadany66.wordpress.com/article/fecal-calprotectin-as-a-marker-in-i2p6c6e8rrui-7Search in Google Scholar